The AtTEnd clinical trial is for women with advanced stage or recurrent endometrial cancer and will assess whether the use of the immune therapy atezolizumab is of additional benefit to current, first line chemotherapy combination.
The international AtTEND trial, led by ANZGOG in Australia and New Zealand, reached its recruitment target of 550 participants last week, including 48 participants from ANZ.
“The study is helping to answer a very important question about the role of immune therapy in non-mismatch repair-deficient tumours, by also seeking to improve the outcomes for women with advanced endometrial cancer.”
AtTEnd Principal Investigator, Associate Professor Yoland Antill
AtTEnd is a double blind randomised placebo controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer. The study is in collaboration with Mario Negri Gynecology Oncology Group (MaNGO) and the NHMRC CTC, and had been recruiting at various clinical sites around Australia and New Zealand before reaching the recruitment target.
We thank all participating women and their families, participating sites, and the NHMRC CTC team for their long-term commitment to the study.
